Overview

• Researchers at The Jackson Laboratory reported survival benefits across human, avian and swine strains, including 2009 H1N1, H5N1 and H7N9.
• Protection extended to immunocompromised animals, with lower lung viral loads and reduced disease severity.
• Therapeutic dosing remained effective several days after infection, with H7N9 survival at 100% through day 3, 70% on day 4, and 60% on day 5.
• Sequencing after 24 days of repeated exposure found no M2e mutations, suggesting a low risk of resistance in the model.
• The team plans to humanize the antibodies and prepare for clinical testing, with the peer-reviewed study published in Science Advances and supported in part by NIH funding.